Warning! GuruFocus detected
1 Severe warning sign
with DXRX.
Try a 7-Day Free Trial
to check it out.
What is a stock summary page? Click here for an overview.
Business Description
Diaceutics PLC
ISIN : GB00BJQTGV64
Description
Diaceutics PLC is a data analytics and implementation services company that services the pharmaceutical industry. It provides the pharma and biotech companies with an end-to-end commercialization solution for the launch of precision medicine, enabled by DXRX The Diagnostic Network. DXRX is the diagnostic commercialization platform designed specifically for precision medicine, integrating multiple pipelines of real-world, real-time diagnostic testing data from a network of labs. These solutions are helping the pharma companies commercialize their precision medicines, enhance their return on investment and ultimately improve patients' lives.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 14.77 | |||||
| Equity-to-Asset | 0.85 | |||||
| Debt-to-Equity | 0.03 | |||||
| Debt-to-EBITDA | 0.8 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 12.39 | |||||
| Beneish M-Score | -2.65 | |||||
| WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 19.9 | |||||
| 3-Year EBITDA Growth Rate | 143.8 | |||||
| 3-Year FCF Growth Rate | 18.6 | |||||
| 3-Year Book Growth Rate | 0.3 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 27.81 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 25.29 | |||||
| 9-Day RSI | 26.51 | |||||
| 14-Day RSI | 29.86 | |||||
| 3-1 Month Momentum % | 19.52 | |||||
| 6-1 Month Momentum % | 12.36 | |||||
| 12-1 Month Momentum % | 40.19 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.85 | |||||
| Quick Ratio | 4.85 | |||||
| Cash Ratio | 2.98 | |||||
| Days Sales Outstanding | 79.16 | |||||
| Days Payable | 54.78 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -0.1 | |||||
| Shareholder Yield % | 0.01 |
Profitability Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 83.3 | |||||
| Operating Margin % | -17 | |||||
| Net Margin % | -10.9 | |||||
| FCF Margin % | -6.09 | |||||
| ROE % | -7.08 | |||||
| ROA % | -6.19 | |||||
| ROIC % | -12.18 | |||||
| 3-Year ROIIC % | -20.46 | |||||
| ROC (Joel Greenblatt) % | -78.25 | |||||
| ROCE % | -8.91 | |||||
| Years of Profitability over Past 10-Year | 7 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Forward PE Ratio | 49.6 | |||||
| PS Ratio | 4 | |||||
| PB Ratio | 2.7 | |||||
| Price-to-Tangible-Book | 4.28 | |||||
| Price-to-Operating-Cash-Flow | 59.05 | |||||
| EV-to-EBIT | -24.14 | |||||
| EV-to-Forward-EBIT | 59.46 | |||||
| EV-to-EBITDA | 62.81 | |||||
| EV-to-Forward-EBITDA | 12.93 | |||||
| EV-to-Revenue | 3.42 | |||||
| EV-to-Forward-Revenue | 2.2 | |||||
| EV-to-FCF | -56.1 | |||||
| Price-to-GF-Value | 0.55 | |||||
| Price-to-Net-Current-Asset-Value | 5.17 | |||||
| Price-to-Net-Cash | 10.33 | |||||
| Earnings Yield (Greenblatt) % | -4.14 | |||||
| FCF Yield % | -1.52 | |||||
| Forward Rate of Return (Yacktman) % | 13.65 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Diaceutics PLC Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil £) | 26.095 | ||
| EPS (TTM) (£) | -0.034 | ||
| Beta | 1.96 | ||
| 3-Year Sharpe Ratio | 0.41 | ||
| 3-Year Sortino Ratio | 0.78 | ||
| Volatility % | 46.39 | ||
| 14-Day RSI | 29.86 | ||
| 14-Day ATR (£) | 0.036286 | ||
| 20-Day SMA (£) | 1.307 | ||
| 12-1 Month Momentum % | 40.19 | ||
| 52-Week Range (£) | 0.95 - 1.51 | ||
| Shares Outstanding (Mil) | 84.52 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Diaceutics PLC Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Diaceutics PLC Stock Events
| Event | Date | Price (£) | ||
|---|---|---|---|---|
| No Event Data | ||||
Diaceutics PLC Frequently Asked Questions
What is Diaceutics PLC(LSE:DXRX)'s stock price today?
The current price of LSE:DXRX is £1.24. The 52 week high of LSE:DXRX is £1.51 and 52 week low is £0.95.
When is next earnings date of Diaceutics PLC(LSE:DXRX)?
The next earnings date of Diaceutics PLC(LSE:DXRX) is 2025-05-09 Est..
Does Diaceutics PLC(LSE:DXRX) pay dividends? If so, how much?
Diaceutics PLC(LSE:DXRX) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers